Fauvet Raffaèle, Boccara Joëlle, Dufournet Charlotte, David-Montefiore Emmanuel, Poncelet Christophe, Daraï Emile
Service de Gynécologie, Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France.
Cancer. 2004 Mar 15;100(6):1145-51. doi: 10.1002/cncr.20098.
The purpose of the current study was to examine the surgical management of women with borderline ovarian tumors and the adequacy of initial staging according to the guidelines of the International Federation of Gynecology and Obstetrics; to evaluate the impact of restaging operations; and to identify risk factors for initial understaging.
In a retrospective French multicenter study, 54 of 360 women with borderline ovarian tumors underwent a restaging operation. After excluding women with initial complete staging (n = 62), epidemiologic, surgical, and histologic parameters and risk of recurrence were compared between women who underwent restaging (n = 54) and those who did not (n = 244).
One hundred fifty (41.6%) of 360 women underwent intraoperative histologic examination, which led to the diagnosis of a borderline tumor in 97 cases (64.7%). Thirty-seven (38.1%) of these 97 women had undergone complete initial staging procedures. A restaging operation was performed for 54 women. A lower median age and a higher rate of conservative treatment were noted in the group that underwent restaging. Eight (14.8%) of the 54 women who underwent restaging had their tumors upstaged: 7 of the 41 cases initially diagnosed as Stage IA tumors were upstaged to Stage IB (n = 3) or to Stage IIA, IIB, IIIA, or IIIC (n = 1 for each); in the eighth case, a Stage IC tumor was upstaged to Stage IIIA. Upstaging tended to be more common in women with serous borderline tumors (P = 0.06) and in women who underwent cystectomy (P = 0.08). There was no difference in recurrence rates according to whether a restaging operation was performed. The recurrence rates after conservative and radical treatment were 15.6% (25 of 160) and 4.5% (9 of 200), respectively (P < 0.001).
Women who initially were diagnosed with Stage IA disease and who had serous borderline tumors or underwent cystectomy appeared to derive the most benefit from restaging surgery. Nonetheless, the indications for restaging surgery remain controversial, as no difference in recurrence rate was observed between women who underwent restaging and those who did not.
本研究的目的是根据国际妇产科联盟的指南,探讨卵巢交界性肿瘤女性的手术治疗及初始分期的充分性;评估再次分期手术的影响;并确定初始分期不足的危险因素。
在一项回顾性法国多中心研究中,360例卵巢交界性肿瘤女性中有54例接受了再次分期手术。在排除初始分期完整的女性(n = 62)后,比较了接受再次分期的女性(n = 54)和未接受再次分期的女性(n = 244)的流行病学、手术和组织学参数以及复发风险。
360例女性中有150例(41.6%)接受了术中组织学检查,其中97例(64.7%)诊断为交界性肿瘤。这97例女性中有37例(38.1%)接受了完整的初始分期程序。54例女性接受了再次分期手术。接受再次分期的组中,年龄中位数较低,保守治疗率较高。接受再次分期的54例女性中有8例(14.8%)肿瘤分期上调:最初诊断为IA期肿瘤的41例中有7例上调至IB期(n = 3)或IIA、IIB、IIIA或IIIC期(各n = 1);在第8例中,IC期肿瘤上调至IIIA期。浆液性交界性肿瘤女性(P = 0.06)和接受囊肿切除术的女性(P = 0.08)中分期上调倾向更常见。是否进行再次分期手术,复发率无差异。保守治疗和根治性治疗后的复发率分别为15.6%(160例中的25例)和4.5%(200例中的9例)(P < 0.001)。
最初诊断为IA期疾病且患有浆液性交界性肿瘤或接受囊肿切除术的女性似乎从再次分期手术中获益最大。尽管如此,再次分期手术的指征仍存在争议,因为接受再次分期的女性和未接受再次分期的女性之间未观察到复发率差异。